December 2022 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.
4 citations
,
February 2022 in “JAAD case reports” The document concludes that low-dose oral minoxidil successfully regrew hair in a patient with permanent hair loss after chemotherapy and stem cell transplant.
4 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” Low-dose oral minoxidil increases hair density and thickness in people with hair loss.
5 citations
,
September 2021 in “Dermatologic Therapy” Oral minoxidil effectively treats female pattern hair loss and is a good alternative to topical minoxidil.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil safely treats hair loss, with hypertrichosis as main side effect.
5 citations
,
December 2020 in “Journal of The American Academy of Dermatology” Minoxidil and spironolactone improve hair density and reduce shedding in girls.
24 citations
,
September 2020 in “Dermatology and therapy” Oral minoxidil 5 mg daily increases hair growth safely in men with hair loss, with minor side effects.
14 citations
,
September 2020 in “Dermatologic Therapy” Oral minoxidil improves hair density in women with androgenetic alopecia, with mild side effects.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” Oral minoxidil promotes hair growth but may cause side effects; needs monitoring.
16 citations
,
May 2020 in “Frontiers in pharmacology” Minoxidil can stop the growth of ovarian cancer cells without harming the heart.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Oral minoxidil and topical minoxidil 5% both effectively improve female-pattern hair loss with safe side effects.
4 citations
,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
52 citations
,
May 2019 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil effectively improves male hair loss with mild side effects.
43 citations
,
March 2019 in “JAMA Dermatology” Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.
53 citations
,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
28 citations
,
March 2017 in “Scientific Reports” Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
31 citations
,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
24 citations
,
April 2014 in “Oncotarget” Minoxidil can reduce functions related to androgen receptors.
48 citations
,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
218 citations
,
January 2013 in “The Lancet Oncology” Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.
67 citations
,
May 2010 in “Journal of The American Academy of Dermatology” Some chemotherapy can cause permanent hair loss.
102 citations
,
February 2008 in “The FASEB Journal” One minoxidil-sensitive potassium channel exists in human hair follicles.
74 citations
,
May 2004 in “Journal of Clinical Hypertension” Minoxidil effectively treats severe hypertension, but watch for side effects.